5,731 results on '"An, Ying"'
Search Results
2. Use of HSC-targeted LNP to generate a mouse model of lethal α-thalassemia and treatment via lentiviral gene therapy
3. Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank
4. Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy
5. Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis
6. Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD
7. The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment
8. C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse
9. The palmitoyltransferase ZDHHC21 regulates oxidative phosphorylation to induce differentiation block and stemness in AML
10. A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia
11. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents
12. Patients with Asian-type DEL can safely be transfused with RhD-positive blood
13. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts
14. The OTUD1-Notch2-ICD axis orchestrates allogeneic T cell–mediated graft-versus-host disease
15. Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease
16. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial
17. BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation
18. Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL
19. Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant
20. All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP
21. YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner
22. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)
23. Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study
24. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
25. Rapid tumor DNA analysis of cerebrospinal fluid accelerates treatment of central nervous system lymphoma
26. Effectiveness and Safety of Hetrombopag-Containing Therapy in Patients with Severe Aplastic Anemia: A Multicenter Real-World Study
27. Thyroid hormone regulates hematopoiesis via the TR-KLF9 axis
28. Focal Adhesion Kinase Inhibitors Reverse the Stromal Adhesion Phenotype of Ikaros-Mutant B-ALL, Induce Apopotosis, and Synergize with ABL1 Tyrosine Kinase Inhibitors: A New Paradigm for Pathogenesis and Therapy of High-Risk B-ALL
29. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma
30. C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse
31. Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank
32. IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.
33. Safety and Efficacy of a-319 (a CD3xCD19 T cell engager) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
34. Innovative Transformer Base Editor (tBE)-Mediated Editing at BCL11A Binding Motif Triggers High Level of γ-Globin Expression with No Observable Off-Target Mutations
35. Short-Term Substitution of Calcineurin Inhibitors (CNIs) with Recombinant Humanized Anti-CD25 Monoclonal Antibody (anti-CD25 rhMAb) As aGVHD Prophylaxis in Cnis Intolerant Patients after Allogeneic Hematopoietic Stem Cell Transplantation
36. RTK-RAS Signaling Pathway Was Enriched in Rare Acute Myeloid Leukemia Patients with t(16;21)(p11;q22)/ FUS::ERG
37. Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML
38. A critical role for Lyn kinase in strengthening endothelial integrity and barrier function
39. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
40. Srsf2P95H initiates myeloid bias and myelodysplastic/myeloproliferative syndrome from hemopoietic stem cells
41. Aged murine hematopoietic stem cells drive aging-associated immune remodeling
42. Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT
43. Enhanced phosphocholine metabolism is essential for terminal erythropoiesis
44. Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2
45. MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice
46. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
47. Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients
48. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies
49. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia.
50. Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.